ORIC Pharmaceuticals Statistics
Total Valuation
ORIC has a market cap or net worth of $406.63 million. The enterprise value is $189.50 million.
Important Dates
The next estimated earnings date is Monday, May 5, 2025, after market close.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ORIC has 71.03 million shares outstanding. The number of shares has increased by 35.52% in one year.
| Current Share Class | 71.03M |
| Shares Outstanding | 71.03M |
| Shares Change (YoY) | +35.52% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 2.00% |
| Owned by Institutions (%) | 73.89% |
| Float | 46.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.79 |
| P/TBV Ratio | 1.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.56, with a Debt / Equity ratio of 0.04.
| Current Ratio | 10.56 |
| Quick Ratio | 10.30 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.73% and return on invested capital (ROIC) is -36.69%.
| Return on Equity (ROE) | -54.73% |
| Return on Assets (ROA) | -33.95% |
| Return on Invested Capital (ROIC) | -36.69% |
| Return on Capital Employed (ROCE) | -57.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.11M |
| Employee Count | 115 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.98% in the last 52 weeks. The beta is 1.24, so ORIC's price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | -58.98% |
| 50-Day Moving Average | 8.69 |
| 200-Day Moving Average | 9.16 |
| Relative Strength Index (RSI) | 30.77 |
| Average Volume (20 Days) | 672,152 |
Short Selling Information
The latest short interest is 13.97 million, so 19.67% of the outstanding shares have been sold short.
| Short Interest | 13.97M |
| Short Previous Month | 13.54M |
| Short % of Shares Out | 19.67% |
| Short % of Float | 30.22% |
| Short Ratio (days to cover) | 15.12 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -142.90M |
| Pretax Income | -101.76M |
| Net Income | -127.85M |
| EBITDA | -141.79M |
| EBIT | -142.90M |
| Earnings Per Share (EPS) | -$1.83 |
Full Income StatementBalance Sheet
The company has $255.96 million in cash and $9.36 million in debt, giving a net cash position of $246.60 million or $3.47 per share.
| Cash & Cash Equivalents | 255.96M |
| Total Debt | 9.36M |
| Net Cash | 246.60M |
| Net Cash Per Share | $3.47 |
| Equity (Book Value) | 243.12M |
| Book Value Per Share | 3.42 |
| Working Capital | 237.40M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$112.66 million and capital expenditures -$1.19 million, giving a free cash flow of -$113.85 million.
| Operating Cash Flow | -112.66M |
| Capital Expenditures | -1.19M |
| Free Cash Flow | -113.85M |
| FCF Per Share | -$1.60 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |